AVALIAÇÃO DOS EFEITOS DO COMPLEXO QUITOSANA FERRO-III SOLÚVEL E INSOLÚVEL EM ANIMAIS TRATADOS COM ALOXANO / EVALUATION OF THE EFFECTS OF THE SOLUBLE AND INSOLUBLE IRON (III) -CHITOSAN COMPLEX IN ANIMALS TREATED WITH ALLOXAN

AUTOR(ES)

Lisiane Magali Rosa Schöninger

DATA DE PUBLICAÇÃO

2007

RESUMO

Chronic Kidney Disease consists of renal lesion and progressive, irreversible loss of glomerular, tubular and endocrine functions of the kidneys. Diseases like Diabetes mellitus and hypertension account for 79% of all cases of final stage renal disease requiring treatments like dialysis or transplant. In Chronic Renal Insufficiency (CRI), the absence of renal function results in hyperphosphatemia in the majority of patients. Dialysis alone is incapable of removing the total quantity of phosphor ingested in a complete meal, due to the low efflux of phosphor which travels from the inner cell space to outer cell space. Agents that bond with the phosphor are effective in decreasing the absorption of intestinal phosphor; however, they may have some adverse side effects such as hypercalcaemia (calcium carbonate, calcium acetate), toxicity (aluminum), extra-osseous calcification and heart disease. Chitosan complexed with Iron (III) and reticulated with glutaraldeid CTS-Fe(III)R proved to be effective in reducing the phosphate in the fluids of hyperphosphatemic mice. This work aims to evaluate the possible effects of soluble and insoluble iron (III) chitosan on the phosphor metabolism of animals with kidney lesion For the experiments, Wistar mice were used, UNIVALI strain, males and females weighing approximately 200 grams each. Kidney lesion was induced in the animals through the diabetogenic drug (alloxan) and phosphate, followed by treatment with soluble and insoluble iron III chitosan via oral solution, for 15 days and through the food for a further 15 and 30 days. The results showed that the experiment, via oral, (soluble with the polymer), both the soluble and the insoluble chitosan were effective, while in the treatment through the food, only the reticulated chitosan showed effective results. With these results, we can conclude that the alloxan, together with the phosphate via oral (water and food), increased the blood phosphate levels. The iron (III) chitosan phosphates, both soluble and insoluble, effectively absorbed the phosphate when the treatment was administered via oral. In the treatment administered through the food, only the insoluble polymer proved effective, both in the 30-day and the 15-day treatment. The animals gender did not affect the study in any noticeable way. The blood iron levels demonstrate the stability of the polymer, since it does not release iron into the circulation.

ASSUNTO(S)

produtos naturais kidney chronic disease hiperfosfatemia farmacia quitosana-ferro(iii) iron (iii) chitosan hyperphosphatemia doença renal crônica

Documentos Relacionados

• AVALIAÇÃO TOXICOLÓGICA CRÔNICA DO POLÍMERO QUITOSANA FERRO(III) SOLÚVEL
• STUDY ON THE INTERACTION OF THE POLYMER CHITOSAN-IRON(III)R WITH INORGANIC IONS IN AQUEOUS MEDIA
• Microesferas de quitosana reticuladas com tripolifosfato utilizadas para remoção da acidez, ferro(III) e manganês(II) de águas contaminadas pela mineração de carvão
• CHARACTERIZATION, STABILITY AND MAGNETIC PROPERTIES OF CHITOSAN IRON POLYMER
• Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities.